Amyloid-beta-targeted monoclonal antibodies probably resulted in little to no difference in cognitive function or in dementia severity.

Early myocarditis onset may predict treatment-related fatality in patients receiving immune checkpoint inhibitor therapy.

Findings based on national survey of adults visiting an emergency department. HealthDay News — Substantial gaps in adult ...

HealthDay News — Intralesional nivolumab seems effective for reducing the size of precancerous oral lesions, according to a study presented at the annual meeting of the American Association for Cancer ...

Two-drug, single-tablet approved for HIV; Dupixent approved for pediatric CSU; novel treatment significantly improves ...

Supported by the CHORD trial, this AAV vector-based therapy delivers a working copy of the OTOF gene and restores otoferlin ...

The expanded approval was based on data extrapolated from Study A, B, and C of the LIBERTY-CUPID program and supportive pharmacokinetics data from the single-arm CUPIDKids study.

The NDA submission included data from the STRIVE-ON trial, which compared GTx-104 with oral nimodipine in patients hospitalized with aSAH.

The PIONEER TEENS trial compared oral semaglutide at maximum tolerated doses with placebo in adolescents aged 10 to 17 years with T2D.

"I’m not going to make that kind of commitment," replied CDC director Kennedy when asked if he'd support vaccine guidance from Dr Schwartz. HealthDay News — During a tense congressional hearing ...

The expanded approval was based on the single-arm, non-randomized, open-label phase 4 PETITE-T1D study, which evaluated the safety and pharmacokinetics of teplizumab.

Sources familiar with the decision who spoke to The Post anonymously said the report had passed the CDC’s scientific review before the delay.